A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postmenopausal women

Menopause

Volumn 21, Issue 3, 2014, Pages 227-235

  Archer, David F ^a   Schmelter, Thomas ^b   Schaefers, Matthias ^b   Gerlinger, Christoph ^b,c   Gude, Kerstin ^b  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b BAYER PHARMA AG   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

17 Estradiol; Drospirenone; Hot flushes; Postmenopausal women; Vasomotor symptoms

Indexed keywords

C REACTIVE PROTEIN; DROSPIRENONE PLUS ESTRADIOL; ESTRADIOL; FOLLITROPIN; GAMMA GLUTAMYLTRANSFERASE; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ARTICLE; BLISTER PACK; BODY MASS; BODY WEIGHT DISORDER; BREAST TENDERNESS; CHOLESTEROL BLOOD LEVEL; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; ENDOMETRIAL THICKNESS; ENDOMETRIUM HYPERPLASIA; FEMALE; FOLLITROPIN BLOOD LEVEL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HORMONAL THERAPY; HOT FLUSH; HUMAN; HYPERTENSION; HYSTERECTOMY; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; MENOPAUSAL SYNDROME; MIDDLE AGED; MONOTHERAPY; NAUSEA; OVARIECTOMY; PATIENT COMPLIANCE; PATIENT SATISFACTION; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; VASOMOTOR DISORDER; WEIGHT GAIN;

ADULT; ANDROSTENES; BIOPSY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENDOMETRIUM; ESTRADIOL; FEMALE; HOT FLASHES; HUMANS; HYDROGEN-ION CONCENTRATION; MIDDLE AGED; PLACEBOS; POSTMENOPAUSE; VAGINA; VAGINAL SMEARS;

EID: 84896723122     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0b013e31829c1431     Document Type: Article

References (31)

1. Stearns V, Ullmer L, Lopez JF, Smith Y, Isaacs C, Hayes D. Hot flushes. Lancet 2002;360:1851-1861.
2. Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004;CD002978.
3. Sturdee DW, Pines A; International Menopause Society Writing Group. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric 2011;14:302-320.
4. The North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause 2012;19:257-271.
5. Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95:s1-s66.
6. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000;62:29-38.
7. Muhn P, Fuhrmann U, Fritzemeier KH, Krattenmacher R, Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann N Y Acad Sci 1995;761:311-335.
8. Fuhrmann U, Krattenmacher R, Slater EP, Fritzemeier KH. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 1996;54:243-251.
9. Schurmann R, Holler T, Benda N. Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens. Climacteric 2004;7:189-196.
10. Lin SQ, Sun LZ, Lin JF, et al. Estradiol 1 mg and drospirenone 2 mg as hormone replacement therapy in postmenopausal Chinese women. Climacteric 2011;14:472-481.
11. Archer DF, Thorneycroft IH, Foegh M, et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005;12:716-727.
12. Warming L, Ravn P, Nielsen T, Christiansen C. Safety and efficacy of drospirenone used in a continuous combination with 17A-estradiol for prevention of postmenopausal osteoporosis. Climacteric 2004;7:103-111.
13. White WB, Pitt B, Preston RA, Hanes V. Antihypertensive effects of drospirenone with 17A-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. Circulation 2005;112:1979-1984.
14. White WB, Hanes V, Chauhan V, Pitt B. Effects of a new hormone therapy, drospirenone and 17-A-estradiol, in postmenopausal women with hypertension. Hypertension 2006;48:246-253.
15. Preston RA, White WB, Pitt B, Bakris G, Norris PM, Hanes V. Effects of drospirenone/17-A estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens 2005;18:797-804.
16. Simoncini T, Genazzani AR. A review of the cardiovascular and breast actions of drospirenone in preclinical studies. Climacteric 2010;13:22-33.
17. Villa P, Suriano R, Ricciardi L, et al. Low-dose estrogen and drospirenone combination: effects on glycoinsulinemic metabolism and other cardiovascular risk factors in healthy postmenopausal women. Fertil Steril 2011; 95:158-163.
18. Gambacciani M, Rosano G, Cappagli B, Pepe A, Vitale C, Genazzani AR. Clinical and metabolic effects of drospirenone-estradiol in menopausal women: a prospective study. Climacteric 2011;14:18-24.
19. Shulman LP, Harari D. Low-dose transdermal estradiol for symptomatic perimenopause. Menopause 2004;11:34-39.
20. Rebar RW, Trabal J, Mortola J. Low-dose esterified estrogens (0.3 mg/day): long-term and short-term effects on menopausal symptoms and quality of life in postmenopausal women. Climacteric 2000;3:176-182.
21. Notelovitz M, Lenihan JP, McDermott M, Kerber IJ, Nanavati N, Arce J. Initial 17A-estradiol dose for treating vasomotor symptoms. Obstet Gynecol 2000;95:726-731.
22. Genazzani AR, Schmelter T, Schaefers M, Gerlinger C, Gude, K. One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17A-estradiol in postmenopausal women [epub ahead of print]. Climacteric 2013.
23. Ettinger B, Ensrud KE, Wallace R, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol 2004;104:443-451.
24. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry. Estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptomsVrecommendations for clinical evaluation. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM135338. pdf. Accessed May 8, 2013.
25. Hunter MS. The Women's Health Questionnaire: a measure of mid-aged women's perceptions of their emotional and physical health. Psychol Health 1992;7:45-54.
26. Guy W. Clinical Global Impressions (CGI) Scale. Washington, DC: APA, 2000 [modified from Rush J et al, Psychiatr Meas].
27. Gerlinger C, Gude K, Hiemeyer F, Schmelter T, Schafers M. An empirically validated responder definition for the reduction of moderate to severe hot flushes in postmenopausal women. Menopause 2012;19:799-803.
28. Panay N, Ylikorkala O, Archer DF, Gut R, Lang E. Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief. Climacteric 2007;10:120-131.
29. Bachmann GA, Schaefers M, Uddin A, Utian WH. Lowest effective transdermal 17A-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2007;110:771-779.
30. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
31. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613.